Following the recommendations of the authorities for the coronavirus pandemic, SARA Pharm has taken the necessary measures to ensure the continuity of its activity. The current projects are on-going. The laboratory is operational and the necessary precautions have been taken to allow the safe reception of samples. We do not foresee any impact on our activity to date. In the event of an evolution, we will not fail to keep you informed.

January 25th, 2021

We are proud to announce that our latest manuscript, part as H2020-MSCA-RISE-2017 consortium (CLATHROPROBES project) was accepted by Molecules. In this paper, we report the in situ spectroelectrochemical cyclic voltammetric studies of the antimony-monocapped nickel(II) and iron(II) tris-pyridineoximates with a labile triethylantimony cross-linking group and Zr(IV)/Hf(IV) phthalocyaninate complexes in order to understand the nature of the redox events in the molecules of heterodinuclear zirconium(IV) and hafnium(IV) phthalocyaninate-capped derivatives. The investigated hybrid molecular systems that combine a transition metal (pseudo)clathrochelate and a Zr/Hf-phthalocyaninate moiety exhibit quite rich redox activity both in the cathodic and in the anodic region. The detailed studies of the abovementioned compounds can read it here:

This work was supported by the European Commission H2020-MSCA-RISE-2017 Grant number, 778245, by the Slovak Grant Agencies APVV (contract Nos. APVV-15-0053, APVV-15-0079, APVV-19-0024 and DS-FR-19-0035) and VEGA (contracts No. 1/0139/20, 1/0718/19, 1/0504/20 and 1/0466/18), and by the Fundação para a Ciência e Tecnologia (FCT) and project UIDB/00100/2020 of Centro de Química Estrutural, Portugal.